The exercise period for warrants of series TO14 B in Episurf commences today

Episurf Medical has opened the exercise period for 503,348,343 warrants (TO14 B) from 9–20 Feb 2026, each exercisable into one B share at SEK 0.03; last trading day for the warrants on Nasdaq Stockholm is 18 Feb 2026. If fully exercised the company would receive approximately SEK 15.1 million before estimated issue costs of ~SEK 0.8 million, and share capital would increase by SEK 5,033,483.43 producing ~23.27% dilution of capital (23.26% of votes). Outcome is to be announced around 23 Feb 2026 and unexercised warrants will expire worthless.

Analysis

Market structure: The immediate winners are Episurf (up to SEK 15.1m gross runway extension) and warrant holders who can convert at SEK 0.03 if the share trades materially above that; losers are existing EPIS B shareholders facing ~23.3% dilution if full exercise occurs. Market-share or pricing power in medtech is unchanged by this capital action, but the financing reduces near-term refinancing risk and therefore reduces forced dilution risk in the short term (weeks–months). Cross-asset effects are negligible for bonds/commodities; expect a localized increase in equity volatility and trading flow on Nasdaq Stockholm around 18–23 Feb, with small SEK flows if foreign holders hedge FX.

Risk assessment: Tail risks include a failed exercise (warrants expire worthless) leaving Episurf short of expected cash, or an unexpected regulatory/clinical setback that would collapse the share price post-exercise; both could force a larger capital raise within 3–12 months. Immediate risks (days) are liquidity squeezes and nominee cutoffs before 20 Feb; short-term (weeks) risk is post-exercise sell pressure from newly issued shares; long-term (quarters) risk is continued operational burn and technology/regulatory execution. Hidden dependencies: nominee settlement timing, guarantor set-off mechanics, and announced real estate acquisitions that may materially change capital needs and dilution math.

Trade implications: Direct short-term trade is event-driven: position around the 18 Feb last-trade date and the 23 Feb exercise outcome—expect elevated volume and 10–30% intraday moves around those dates. If you believe >50% of warrants will be exercised, a small long (1–3% portfolio) in EPIS B pre-outcome is asymmetrically attractive given SEK 15m cash injection vs dilution; if you expect low exercise (<30%), favor selling/shorting post-outcome anticipating additional raises. Options/warrant plays: buy short-dated (<=1 month) EPIS call exposure only if liquidity allows, or sell-to-open expiring warrants if you can delta-hedge shares; set strict stops (15–20%).

Contrarian angle: The market may over-penalize for dilution; a full exercise injects capital at effectively zero cost (SEK 0.03) and could extend runway by multiple quarters—if burn is <SEK 5m/month, full exercise covers ~3 months after costs. Conversely, consensus could under-price the operational risk from the real estate moves; use the 23 Feb outcome as a binary catalyst—buy if exercise rate >50% and clinical/regulatory calendar looks intact, short if exercise <30% or if management signals further capital needs within 90 days.

Key Decisions for Investors

• Establish a tactical long in EPIS B (2% of portfolio) if current market price is <= SEK 0.06 and you expect >50% warrant exercise; target +30% in 30–90 days, hard stop -20%.
• If you hold TO14 B warrants: exercise only if you can fund at SEK 0.03 and the share price is >= SEK 0.06 (to cover fees and execution risk); otherwise sell warrants by 18 Feb to capture residual time value or avoid dilution outcome exposure.
• Implement a short post-outcome trade (size 1–2%) conditional: short EPIS B if announced exercise proportion is <30% or management signals additional capital needs within 90 days; cover on either a new financing announcement or a 25% move against you.
• Watch the 23 Feb exercise publication and two-week nominee cutoff signals as binary catalysts—if exercised shares >60% (company cash >= SEK 9m net) rotate into small-cap Swedish medtech longs (+1–2%) vs cash for 60–120 day tactical carry.